✅ PoCMAP
✅ Allogeneic
✅ Autologous
✅ Allogeneic
✅ Autologous
✅ PoCMAP
✅ Allogeneic
✅ Autologous
✅ Allogeneic
✅ Autologous
✅ PoCMAP
✅ Allogeneic
✅ Autologous
✅ Allogeneic
✅ Autologous
At Thrafford, we’re pioneering the next generation of cell therapy manufacturing — making treatments more affordable, scalable, and accessible worldwide.
Our Three-Pillar Approach
Affordability
Allogeneic donor-derived therapies reduce manufacturing cost by enabling multi-patient batches.
One batch — many patients.
Scalability
Our modular platform delivers up to 40× capacity using parallel multi-batch processing systems.
40× production capacity.
Accessibility
India’s first point-of-care CAR-T manufacturing system — enabling hospital-based therapy production.
Therapies closer to home.
The PoCMAP Advantage
- Decentralized manufacturing at hospitals.
- Parallel multi-batch processing increases output.
- Compatible with CAR-T, NK, dendritic cell systems.
- Real-time sterility and quality control integration.
- Reduced logistics and fewer freeze–thaw cycles.
Applications
- CAR-T therapies
- NK & dendritic cell therapies
- Autoimmune & infectious diseases
- Solid tumors & next-gen gene editing